Differential teratogenic response of mouse embryos to receptor selective analogs of retinoic acid.
Early events that initiate teratogenesis by Accutane or other retinoids in mammalian embryos remain unknown. It would be helpful for mechanistic considerations to know whether or not retinoids act through retinoid receptor-dependent pathways, and if they do, which of the two families of receptors (retinoic acid receptors - RARalpha, beta, gamma or retinoid X receptors - RXRalpha, beta, gamma) are more likely involved. We previously used an in vitro bioassay to demonstrate that those retinoid analogs with binding affinity and transactivational activity limited only to the RXRs have a low potential as teratogens. Here, we have extended the study to examine teratogenicity, in pregnant mice, of a number of synthetic retinoids with varying degrees of receptor selectivity. The ability of each compound to induce fetal limb and craniofacial defects after a single exposure on day 11 of gestation was assessed and compared to that of all-trans retinoic acid (RA). The highest dose selected was 100 mg/kg maternal body weight since such a regimen of all-trans RA affects virtually every exposed embryo without any indication of maternal toxicity. We found that although all RAR agonists were strong teratogens, their potencies varied over a wide magnitude. The teratogenic potencies and receptor transactivation profiles of RAR agonists were not directly correlated since compounds with similar receptor activities presented major differences in potencies. Three compounds were exclusively RXR agonists, and these were not teratogenic under our experimental conditions. Two additional compounds which turned out to be non-teratogenic were distinguished by the fact that they activated neither RARs nor RXRs. These data indicate that although RAR-dependent mechanisms are likely involved in retinoid-induced teratogenesis, there are additional factors which determine teratogenic potency. The absence of teratogenic response in the case of RXR agonists suggests that risk-benefit analyses of such receptor-selective compounds may be fruitful in further studies.
Kochhar
D M
DM
Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107 USA.
Jiang
H
H
Penner
J D
JD
Beard
R L
RL
ChandraratnaAS
D000818:Animals; D002356:Cartilage / Q000196:embryology; D005121:Extremities / Q000196:embryology; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D011247:Pregnancy; D018168:Receptors, Retinoic Acid / Q000502:physiology*; D047488:Retinoid X Receptors; D015398:Signal Transduction; D013723:Teratogens / Q000737:chemistry*; D014157:Transcription Factors / Q000502:physiology*; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000633:toxicity
D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D013723:Teratogens; D014157:Transcription Factors; D014212:Tretinoin